New patent granted for Natreon

The nutritional ingredient company received a US Patent for a natural bioactive for prevention or treatment of body weight gain

Natreon, a nutritional ingredient company, was granted a US Patent for 3-hydroxy-dibenzo-α-pyrone (3-OH-DBP), also known as Urolithin B, a natural bioactive present in shilajit, for prevention and/or treatment of body weight gain. International patents are pending.

Natreon was also issued a US patent in 2014 on a combination of 3,8-dihydroxydibenzo-α-pyrone (3,8-(OH)2-DBP), also known as Urolithin A, or 3-OH-DBP (Urolithin B) and CoQ10/Ubiquinol, as mitochondria-targeted antioxidants for treatment of mitochondrial disorders.

Both DBPs (urolithins) are bioactive components of shilajit and the fulvic acids in shilajit have the core nucleus made up of DBPs. Shilajit is a mineral-rich substance found in Himalayan and Altai mountain areas and used in Ayurvedic medicine. DBPs are present in shilajit in free form as well as in conjugation with chromoproteins.

There has been a significant amount of research conducted on urolithins recently. One of the most recent theories prevailing is that the ellagitannins from the diet, especially fruits such as pomegranate, are converted to urolithins by the microbiome in the GI tract, which are then absorbed into the blood stream, providing immunity.

Natreon’s research at Ohio State University Wexner Medical Center has shown that DBPs are present in animal tissue and have significant mitochondrial activity. Natreon is planning clinical studies on these compounds.

Natreon’s scientific research includes process optimisation, development of chromatographic analytical methods such as HPLC, HPTLC, GC-MS and LC-MS-MS for standardisation, development of marker compounds, and pharmacological studies.